Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Sarcoma × trebananib × Clear all

Phase

Status

Sponsor Class

NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 6 Fallopian Tube Neoplasms 6 Neoplasms 5 Neoplasm Metastasis 5 Carcinoma 4 Gastrointestinal Neoplasms 2 Breast Neoplasms 2 Stomach Neoplasms 1 Sarcoma 1 Renal Insufficiency 1 Rectal Neoplasms 1 Kidney Diseases 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Tumors 1 Advanced Hepatocellular Carcinoma 1

Interventions

Doxorubicin 30 pembrolizumab 12 Gemcitabine 11 Irinotecan 9 pazopanib 8 eribulin 8 Trabectedin 8 olaratumab 7 Cyclophosphamide 6 anlotinib 5 Injections 5 Docetaxel 5 ridaforolimus 4 Temozolomide 4 Nivolumab 4 Ifosfamide 4 Fluorouracil 4 Carboplatin 4 Bevacizumab 4 tazemetostat 3 belinostat 3 TH 302 3 Paclitaxel 3 Ipilimumab 3 Epirubicin 3 Drug Therapy 3 Dacarbazine 3 DOXO-EMCH 3 trastuzumab deruxtecan 2 toripalimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01992341 2014-09-23

AMG 386 Drug-Drug Interaction Study With Paclitaxel

Amgen

Phase 1 Completed

Carcinoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡